CoChat
Sign Up
Cited by 621Pancreatic and Hepatic Oncology ResearchPancreatic function and diabetesMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 36 of the 40 references it cites were found in a registry or an index.

Prevalence and Clinical Profile of Pancreatic Cancer–Associated Diabetes Mellitus

Open access
Pannala, Rahul, Leirness, Jeffery B., Bamlet, William R., Basu, Ananda, Petersen, Gloria M., Chari, Suresh T.·2008·Gastroenterology
DOI 10.1053/j.gastro.2008.01.039PMC PMC2323514
Open this paper in CoChat — free accountOpen PDF

Abstract

Background & aims Information on the clinical profile of pancreatic cancer (PaC) associated diabetes (DM) is limited. We compared the prevalence and clinical characteristics of DM in subjects with and without PaC.Methods We prospectively recruited 512 newly diagnosed PaC cases and 933 controls of similar age, who completed demographic and clinical questionnaires and had fasting blood glucose (FBG) levels measured at recruitment and after pancreaticoduodenectomy (n = 105). Subjects with a FBG level >126 mg/dL or who were on antidiabetic treatment were classified as having DM.Results DM was more prevalent (47% vs 7%; P < .001) and predominantly of new onset (<2-year duration) (74% vs 53%; P = .002) among cases compared with controls. Among PaC cases, those with DM (n = 243) were older (68 +/- 10 vs 64 +/- 12 years; P < .001), reported higher usual adult body mass index (30 +/- 6 vs 27 +/- 5 kg/m(2); P < .001), and had a greater frequency of family history of DM (47% vs 31%; P < .001) compared with those without DM (n = 269). After pancreaticoduodenectomy, while DM resolved in 17 of 30 patients (57%) with new-onset DM, its prevalence was unchanged in patients with long-standing DM (n = 11) (P = .009).Conclusions PaC is a powerful diabetogenic state; DM associated with PaC is often new-onset, resolves following cancer resection, and appears to be associated with conventional risk factors for DM. New-onset DM in patients with PaC is likely induced by the tumor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2008.01.039

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

4 of the 40 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

See all 621

Related

See all

Metadata

Authors
Pannala, R., Leirness, J. B., Bamlet, W. R., Basu, A., Petersen, G. M., & Chari, S. T.
Affiliations
Mayo Clinic (US)
Corresponding author
Chari, Suresh T.
ORCID
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2008-04
Volume
134
Issue
4
Pages
981-987
ISSN
0016-5085 (ISSN-L)
DOI
10.1053/j.gastro.2008.01.039
PMC
PMC2323514
OpenAlex
W1998608669
Cited by
621
References
40
Citations by year
2026: 25 · 2025: 45 · 2024: 32 · 2023: 50 · 2022: 40 · 2021: 59 · 2020: 47 · 2019: 42 · 2018: 39 · 2017: 36 · 2016: 20 · 2015: 29 · 2014: 35 · 2013: 26 · 2012: 38
FWCI
10.03
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P50 CA 10270, P50CA102701, R01CA100685)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
pancreatic cancer, diabetes mellitus, new-onset diabetes, pancreaticoduodenectomy, fasting blood glucose, body mass index, family history of diabetes, diabetes risk factors, cancer-associated diabetes
MeSH terms
Aged, Blood Glucose, Diabetes Mellitus, Female, Humans, Male, Neoplasm Staging, Pancreatic Neoplasms, Prospective Studies, Surveys and Questionnaires, Risk Factors, United States, Prevalence, Pancreaticoduodenectomy, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review